Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

4 years ago
Pharma
FDA+

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

4 years ago
Pharma

Watch out Bay­er, Roche is com­ing for you with a dis­count price ri­val to the tu­mor ag­nos­tic drug you got from Loxo

4 years ago
R&D

Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

4 years ago
People
Pharma

Re­gen­eron puts fin­ish­ing touch­es on $800M ex­pan­sion project close to home

4 years ago
R&D

A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug in DNA dam­age re­pair

4 years ago
R&D

FDA en­dors­es new reg­i­men for dead­ly drug-re­sis­tant tu­ber­cu­lo­sis ram­pant in de­vel­op­ing world

4 years ago
R&D
Pharma

Macro­Gen­ics vs Mer­ck: An un­der­dog plans a pre­mier bout with the heavy­weight cham­pi­on of the PD-1 class

4 years ago
R&D

AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

4 years ago
People

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

4 years ago
Deals

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

4 years ago
R&D
Pharma

Pow­er­ful Re­pub­li­can Chuck Grass­ley at­tacks No­var­tis CEO Narasimhan for ‘rep­re­hen­si­ble’ de­ci­sion to hide da­ta

4 years ago
People

Lit­tle De­ci­phera will hus­tle pos­i­tive PhI­II sur­vival da­ta on lead can­cer drug to the FDA in search of its first OK — shares soar

4 years ago
R&D

Make that 2 new US Big Phar­ma chiefs to­day, as No­var­tis re­makes top team

4 years ago
People
Pharma

Shift­ing fo­cus to on­col­o­gy, GSK re­cruits a can­cer vet as new chief of US phar­ma­ceu­ti­cals — adding an­oth­er woman to the top ranks of bio­phar­ma

4 years ago
People

Hu­mana takes aim at Mallinck­rodt's 'ill-got­ten' Ac­thar gains in law­suit

4 years ago
Pharma
FDA+

A top an­a­lyst spot­lights a wave of biotech star­tups look­ing to cat­a­pult on­to Nas­daq — or get bought out

4 years ago
Financing

Am­gen at­tor­neys win a megablock­buster patent case, deal­ing No­var­tis a se­vere set­back on biosim­i­lars play

4 years ago
Pharma

US sen­a­tors ac­cuse No­var­tis ex­ecs of greed for hid­ing ma­nip­u­lat­ed Zol­gens­ma da­ta — and the next step could af­fect the in­dus­try

4 years ago
Pharma
FDA+

Melin­ta chief John John­son jumps ship — with the chair­man — from an­oth­er trou­bled an­tibi­otics play

4 years ago
People

Mys­tery solved? Nek­tar chief says 'soft­en­ing' in pa­tient re­spons­es to be­m­peg was a CMC is­sue — spurring a rout

4 years ago
R&D

Sarep­ta shares slammed on re­port gene ther­a­py Duchenne MD pa­tient was hos­pi­tal­ized, but the com­pa­ny says it is 'er­ro­neous'

4 years ago
R&D
Pharma

The FDA’s very pub­lic slap of No­var­tis’ red face is a warn­ing to the en­tire in­dus­try — don’t down­play it

4 years ago
Bioregnum
Opinion

Bay­er is go­ing all in on next-gen stem cell biotech Blue­Rock, buy­ing out Ver­sant and founders for $600M

4 years ago
Deals
Cell/Gene Tx
First page Previous page 185186187188189190191 Next page Last page